Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
AI Sentiment
Highly Positive
8/10
as of 12-05-2025 4:00pm EST
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | PHOENIX |
| Market Cap: | 10.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 124.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.69 - $6.90 | Next Earning Date: | 11-07-2025 |
| Revenue: | $6,000 | Revenue Growth: | -45.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CELZ Breaking Stock News: Dive into CELZ Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how CELZ stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CELZ Creative Medical Technology Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.